Latest Information Update: 05 Feb 2008
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Granulocyte colony stimulating factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Jan 2008 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 18 May 1995 Suspended-Preclinical for Cancer in United Kingdom (unspecified route)